On Wednesday, Partex, the first Data to Drugs pharma platform, and Parexel, one of the biggest clinical research organizations (CROs) in the world, announced a preferred strategic alliance to use artificial intelligence (AI)-powered solutions to accelerate drug discovery and development for biopharmaceutical customers globally and de-risk the assets in their portfolios.
According to a news release, Parexel and Partex have a shared goal to enhance patient outcomes and foster a culture of ongoing innovation via the use of cutting-edge technology, data-driven insights, and collaborative ecosystems.
The company asserted that Partex’s big data and AI capabilities, in conjunction with Parexel’s extensive global expertise across Phase I to IV clinical development, are expected to further advance the efforts of drug developers working to understand the likelihood of clinical success of assets in their portfolio and recommend other disease indications for which their assets may be clinically viable.
Anticipating the exploratory medicines that will be available as safe and efficient therapeutic choices is one of the biggest and most difficult difficulties in drug development. By highlighting the assets with the highest likelihood of clinical success, our cutting-edge partnership with Partex helps to address this challenge, allowing customers to concentrate their time and resources where it will benefit patients the most, said Jamie Macdonald, Chief Executive Officer, Parexel in a statement.
Under the terms of the alliance, Parexel will serve as the chosen CRO provider for the Partex group of companies’ clinical trial execution. Through the Partex-validated AI platform, the parties will also work together to improve clinical trial execution for customers, enhancing and extending Parexel’s current AI tools and capabilities.
“By merging Parexel’s renowned clinical research skills with Partex’s cutting-edge AI capabilities, we want to accelerate the delivery of safe and effective medications to patients throughout the world, eventually changing the biopharmaceutical landscape. In a statement, Dr. Gunjan Bhardwaj, CEO of Partex, said, “We eagerly anticipate the presentation of new value-generating methodologies and ground-breaking inventions as a result of our collaboration.
The strategic agreement, according to the company, represents a significant advancement in utilizing artificial intelligence and big data to transform the pharmaceutical sector and provide patients in need with life-changing medications.
